Nanocarriers provide tumor‐specific concentration of anti‐androgens, AR degraders, or AR‐axis siRNAs and allow triplet combinations (e.g., ADT + TNP loaded with taxane + immunomodulator). The gene discussed is AR; the disease is neoplasm.